Mainstay Medical Notice of Results
12 Septiembre 2019 - 10:00AM
UK Regulatory
TIDMIRSH
Mainstay Medical Announces Date for 2019 Half Year Results
Mainstay Medical International plc ("Mainstay" or the "Company",
Euronext Paris: MSTY.PA and Euronext Dublin: MSTY.IE), a medical
device company focused on bringing to market ReActiv8®, an
implantable neurostimulation system to treat disabling Chronic Low
Back Pain, announces that the Company will release its 2019 Half
Year results on 20 September 2019 at 07:00 BST (02:00 EDT, 08:00
CEST).
Jason Hannon, Chief Executive Officer, and Matthew Onaitis,
Chief Financial Officer, will host a conference call and Q&A
for analysts and investors at 13:00 BST (08:00 EDT, 14:00 CEST) on
the day. The call will be conducted in English and a replay will be
available for 30 days. Dial-in details for the call are:
Europe: +44 333 300 0804
Ireland: +353 1 431 1252
France: +33 170750711
Germany: +49 6913803430
USA: +1 6319131422
Participant PIN: 34020721#
The results press release will be available on the 'Investors'
section of the Mainstay Medical website at:
www.mainstay-medical.com/investors
- End -
About Mainstay
Mainstay is a medical device company focused on bringing to
market an innovative implantable neurostimulation system,
ReActiv8®, for people with disabling Chronic Low Back Pain (CLBP).
The Company is headquartered in Dublin, Ireland. It has
subsidiaries operating in Ireland, the United States, Australia,
Germany and the Netherlands, and is listed on regulated market of
the Euronext Paris (MSTY.PA) and the Euronext Growth market of
Euronext Dublin (MSTY.IE).
About Chronic Low Back Pain
One of the root causes of CLBP is impaired control by the
nervous system of the muscles that dynamically stabilize the spine.
ReActiv8 is designed to electrically stimulate the nerves
responsible for contracting these muscles to improve dynamic spine
stability, allowing the body to recover from CLBP.
People with CLBP usually have a greatly reduced quality of life
and score significantly higher on scales for pain, disability,
depression, anxiety and sleep disorders. Their pain and disability
can persist despite the best available medical treatments, and only
a small percentage of cases result from an identified pathological
condition or anatomical defect that may be correctable with spine
surgery. Their ability to work or be productive is seriously
affected by the condition and the resulting days lost from work,
disability benefits and health resource utilization put a
significant burden on individuals, families, communities, industry
and governments.
Further information can be found at www.mainstay-medical.com
CAUTION - in the United States, ReActiv8 is limited by federal
law to investigational use only.
PR and IR Enquiries:
LifeSci Advisors, LLCBrian RitchieTel: + 1 (212) 915-2578Email:
britchie@lifesciadvisors.com
FTI Consulting (for Ireland)Jonathan Neilan or Patrick
BerkeryTel: +353 1 765 0886Email: mainstay@fticonsulting.com
Euronext Growth Advisers:DavyFergal Meegan or Barry MurphyTel:
+353 1 679 6363Email: fergal.meegan@davy.ie or
barry.murphy2@davy.ie
View source version on businesswire.com:
https://www.businesswire.com/news/home/20190912005409/en/
This information is provided by Business Wire
(END) Dow Jones Newswires
September 12, 2019 11:00 ET (15:00 GMT)
Mainstay Medical (LSE:0QUD)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Mainstay Medical (LSE:0QUD)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024